I liked your .68 near term price target for AMBS. I agree with that number. For me, the assumptions are US partner, data, rev guidance. That would likely get it there. Ex-US distribution partner would blow it out. All of that is just Lympro. So, I agree with your other targets and possible no RS if Eltoprazine and MANF deliver. Aldo, TBI, Nuropro, Phenoguard, and maybe a surprise. In good shape here. He just needs to push the snowball down the hill.